Login to Your Account

Gilead Moving into Kinases; Buying CGI for up to $120M

By Jennifer Boggs

Monday, June 28, 2010
In the ongoing efforts to diversify its pipeline, Gilead Sciences Inc. offered up to $120 million for privately held kinase company CGI Pharmaceuticals Inc., a deal that offers some long-term growth potential though is unlikely to distract investors from much-anticipated late-stage data that could expand the firm's lucrative HIV franchise. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription